BonneVie MD Aesthetics
105 West Wilson Bridge Road · Worthington, OH 43085
5.0(61 Google reviews · 16 in past year)
Akribis Veins & Vitality: Amanda Cooper, MD · 121 West Wilson Bridge Road · Worthington, OH 43085
4.8· 116 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Akribis Veins & Vitality is a vein and aesthetics practice in Worthington, Ohio, where its website names Dr. Amanda Cooper, MD, as a board-certified radiologist and vein expert. The site says vein health is where the practice started and lists treatments such as radiofrequency vein ablation, phlebectomy and VenaSeal, along with aesthetic services including non-surgical body sculpting; the listing also shows weight-loss care and hormone care. On Google it has a 4.8-star rating across 116 reviews dating back to 2019, with 9 in the past year. Reviewers mention the staff most of all, in 62 reviews, followed by the providers' knowledge.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2026-06-02. Read the reviews themselves on the practice's Google listing.
Rated ★4.8 across 116 Google reviews. Of the 100 reviews we analyzed, 94 (94%) are positive (4–5★) and 6 (6%) are negative (1–2★).
derik o.★★★★★2026-06-02I highly recommend! The best support and care you could ask for! Everyone is so polite and truly do care. They remember you, your kids, and all the important details specific to you! They are like family! Dr.Cooper and her staff give 100%. Always.
Anne R.★★★★★2026-04-28I had an amazing experience with Dr Cooper and her team. Very genuine and kind-Thank you
Katie F.★★★★★2026-03-10I found Dr. Cooper and her team when I needed vein surgery. The procedure went very well, and each member of the care team was fantastic before, throughout, and following my procedures. I’ve since returned for other services, which have been hugely impactful for my overall health and wellness. My experiences are consistent: they are so welcoming, communicative, thoughtful, and caring. I’ve recommended them highly to others and would certainly continue to do so.
Carol D.★★★★★2026-02-05Dr. Cooper and staff provided a well informed and comfortable experience for my first rosacea treatment. The office is stunningly appointed and all new state of the art equipment. Dr. Cooper is very meticulous during all of my procedures. I trust her advice and she answers all of my questions. A definite endorsement for her practice!
Sarah P.★★★★★2026-01-16Dr. Cooper and her staff are thorough, professional and kind.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
105 West Wilson Bridge Road · Worthington, OH 43085
5.0(61 Google reviews · 16 in past year)
1000 North High Street · Worthington, OH 43085
4.9(210 Google reviews · 87 in past year)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs